PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
4.31%
Gross profit growth of 4.31% while Biotechnology median is zero. Walter Schloss might see a slight advantage that could be built upon.
8.25%
EBIT growth exceeding 1.5x Biotechnology median of 2.46%. Joel Greenblatt would examine whether a unique competitive edge supports this outperformance.
8.25%
Operating income growth exceeding 1.5x Biotechnology median of 2.85%. Joel Greenblatt would see if unique processes drive exceptional profitability.
12.55%
Net income growth exceeding 1.5x Biotechnology median of 4.07%. Joel Greenblatt would check if brand strength or cost advantages fuel this outperformance.
15.52%
EPS growth exceeding 1.5x Biotechnology median of 8.70%. Joel Greenblatt would confirm if consistent earnings expansion underpins these gains.
15.52%
Diluted EPS growth exceeding 1.5x Biotechnology median of 9.09%. Joel Greenblatt would confirm if strong net income growth or buybacks drive outperformance.
3.21%
Share growth above Biotechnology median by more than 2x. Jim Chanos would suspect over-dilution or repeated equity raises.
3.21%
Diluted share growth above 2x Biotechnology median. Jim Chanos would suspect undue issuance or heavy employee stock compensation.
No Data
No Data available this quarter, please select a different quarter.
18.46%
OCF growth exceeding 1.5x Biotechnology median of 5.44%. Joel Greenblatt would see if a superior business model or cost structure drives strong cash generation.
18.52%
FCF growth exceeding 1.5x Biotechnology median of 4.90%. Joel Greenblatt would see if high profitability or prudent capex drives outperformance.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
80.04%
OCF/share CAGR of 80.04% while Biotechnology median is zero. Walter Schloss might see a modest edge that can add up if momentum improves.
77.11%
OCF/share CAGR of 77.11% while Biotechnology median is zero. Walter Schloss might see a slight advantage that can compound if momentum builds.
-27.06%
Negative 3Y OCF/share CAGR while Biotechnology median is 0.00%. Seth Klarman would check whether it’s cyclical or a firm-specific problem.
72.83%
Net income/share CAGR of 72.83% while Biotechnology median is zero. Walter Schloss might see a marginal edge that can grow if the firm invests wisely.
70.62%
Net income/share CAGR of 70.62% while Biotechnology median is zero. Walter Schloss might see a modest advantage that can expand mid-term.
-36.68%
Negative 3Y CAGR while Biotechnology median is 12.04%. Seth Klarman might see a pressing concern if the rest of the sector is stable or growing.
109.68%
Equity/share CAGR of 109.68% while Biotechnology median is zero. Walter Schloss might see a modest advantage in net worth accumulation that could matter long term.
-48.78%
Negative 5Y equity/share growth while Biotechnology median is 0.00%. Seth Klarman suspects firm-specific weaknesses if peers grow equity mid-term.
-45.28%
Negative 3Y equity/share growth while Biotechnology median is -4.15%. Seth Klarman sees a short-term weakness if peers still expand net worth.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Dividend reductions while Biotechnology median grows. Seth Klarman sees a near-term disadvantage if peers maintain or raise payouts.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-10.20%
Assets shrink while Biotechnology median grows. Seth Klarman might see a strategic refocus or potential missed expansion if demand is present.
-20.44%
Negative BV/share change while Biotechnology median is -10.86%. Seth Klarman sees a firm-specific weakness if peers accumulate net worth.
-5.39%
Debt is shrinking while Biotechnology median is rising. Seth Klarman might see an advantage if growth remains possible.
4.88%
R&D growth of 4.88% while Biotechnology median is zero. Walter Schloss wonders if a slight increase yields a meaningful competitive edge.
-40.17%
SG&A decline while Biotechnology grows. Seth Klarman sees potential cost advantage or a risk if it hurts future growth.